The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients

Haematologica

Volumn 82, Issue 3, 1997, Pages 351-353

  Celesti, Lidia ^a   Clavio, Marino ^a   Poggi, Alessia ^b   Casciaro, Salvatore ^b   Vallebella, Emanuela ^a   Gobbi, Marco ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cyclophosphamide; Dexamethasone; Refractory myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; MALE; MULTIPLE MYELOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031452473     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Buzaid AC, Durie BG. Management of refractory myeloma: a review. J Clin Oncol 1988; 6:889-905.
2. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-6.
3. Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105:8-11.
4. Epstein J, Xiao H, Koba B. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74:913-7.
5. Palumbo A, Boccadoro M, Triolo S, Bruno B, Pileri A. Cyclophosphamide (3.6 μg/sqm) therapy with G-CSF support for resistant myeloma. Haematologica 1994; 79:513-8.
6. Clavio M, Casciaro S, Gatti AM, et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996; 81:238-44.
7. Bergsagel DE, Cowan DH, Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can Med Ass J 1972; 107:851-5.
8. Leoni F, Golli S, Salti F, Teodori P, Rossi Ferrini PL. Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma. Br J Haematol 1991; 77:180-4.
9. Pileri A, Palumbo A, Boccadoro M. Current therapeutic options for multiple myeloma. Haematologica 1996; 81:291-4.
10. Caligaris Cappio F, Cavo M, De Vincentiis A, et al. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. Haematologica 1996; 81:356-73.